Medically reviewed by the Celva medical team · June 2026
What response
looks like, actually.
Response to cell therapy in complex disease is rarely dramatic. Often it's measurable. Sometimes it's absent. An honest map of what to watch, what to hope for, and what to stop hoping for.
Complex disease remodels slowly. The response curve is longer than joint or IV cases.
Meaningful shifts look like incremental function gains, not reversal.
Some patients show measurable response. A meaningful minority don't. We track both.
What won't
happen.
There is no version of this therapy that reverses established disease, restores lost tissue, or acts as a cure. Clinics that frame it otherwise are misleading their patients.
In the right indications with reasonable candidates, the biology can modulate inflammation, support your body's own repair, and create margin where margin exists. That is the honest scope. We build on allogeneic umbilical-cord MSCs specifically because they secrete higher levels of neurotrophic, immune-modulating, and pro-repair signaling factors than other cell sources, but a richer signaling profile is still signaling, not tissue replacement.
For established structural disease, the physician team will tell you plainly what is realistic for your case. Advanced tissue loss is outside what cell signaling can address.
"Partial, measurable, gradual" is the honest ceiling, and when it arrives, it's meaningful. Dramatic reversal narratives are not what we sell, because they are not what we see.
Signals that
something is shifting.
Symptom-specific
Matched to your diagnosis: less neuropathic burning, steadier autonomic function, better exertional tolerance, or fewer inflammatory flares.
- Validated symptom scales
- Patient-kept diary
- Tracked at 90 / 180 / 360 days
Functional
Walking tolerance, fine-motor tasks, sleep quality. Function moves before dramatic symptom change often.
- 6-minute walk
- Activity re-introduction
- Sleep architecture
Objective
Where applicable, nerve conduction, imaging metrics, inflammatory markers.
- NCV when indicated
- Labs at 6 / 12 months
- Repeat imaging on return for re-treatment
Non-response
is real.
A meaningful minority of even well-screened complex-disease candidates see no measurable response at nine months. We structure follow-up to identify that, not to paper over it.
When a case is not responding, the next conversation is about what that means, what alternatives exist, and whether any further intervention from us has rationale. Often the answer is no.
First check-in
Baseline comparison. Response too early to be conclusive. Continue structured follow-up.
Mid-window
First meaningful read on response direction. Adjust follow-up plan accordingly.
Definitive read
Response is what it's going to be. Decision point on maintenance, trial enrollment, or stopping.
Expectation
questions.
Q.01Will this reverse my diagnosis?
Q.02How will I know if it's working?
Q.03Is another session worth trying if the first doesn't respond?
Keep
reading.
Measurable
honesty.
If you're comfortable with "partial, measurable, gradual" as the ceiling, and you meet the candidacy profile, submit for evaluation.